Friday, July 10, 2026

Patent directory · USPTO A61K / A61P

Patents matching “antibody”

426 pharma patents match "antibody" in our USPTO index (A61K/A61P) — applicant, grant date, expiration, and drug links.

Matches 426
Index total 30,257
Page 1 / 18

Quick answer

This filtered view shows 426 pharmaceutical patents matching "antibody" in our USPTO PatentsView index (CPC A61K/A61P). Search matches patent number, title, applicant, and CPC classification codes.

Patent results

426 results for “antibody” · 30,257 patents in full index Clear search

  1. US 20260144884

    ANTI-LRRC15 ANTIBODY DRUG CONJUGATES

    BRISTOL MYERS SQUIBB CO [US] · Granted May 28, 2026 · Expires May 23, 2046

    granted
  2. US 20260116972

    CROSS-SPECIES-SPECIFIC PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALINXCD3, EPCAMXCD3, IGF-1RXCD3 OR FAPALPHAXCD3 BISPECIFIC SINGLE CHAIN ANTIBODY

    AMGEN RES MUNICH GMBH [DE] · Granted Apr 30, 2026 · Expires Apr 25, 2046

    granted
  3. US 20260115307

    ANTI-FUCOSYL-GM1 ANTIBODY DRUG CONJUGATES

    BRISTOL MYERS SQUIBB CO [US] · Granted Apr 30, 2026 · Expires Apr 25, 2046

    granted
  4. AU 2024342196

    NOVEL ECTEINASCIDIN DERIVATIVE, PREPARATION METHOD THEREFOR AND USE THEREOF, AND ANTIBODY-DRUG CONJUGATE AND USE THEREOF

    ABBVIE GROUP HOLDINGS LTD [BM] · Granted Apr 2, 2026 · Expires Mar 28, 2046

    granted
  5. AU 2024276234

    METHODS OF TREATMENT USING ANTI-C-MET ANTIBODY DRUG CONJUGATES

    ABBVIE MFG MANAGEMENT UNLIMITED COMPANY [IE] · Granted Dec 4, 2025 · Expires Nov 29, 2045

    granted
  6. US 2025325692

    METHODS OF TREATMENT USING ANTI-SEZ6 ANTIBODY DRUG CONJUGATES

    ABBVIE INC [US] · Granted Oct 23, 2025 · Expires Oct 18, 2045

    granted
  7. US 12427201

    Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates

    Sutro Biopharma, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  8. US 12428487

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonicleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Sep 30, 2025 · Expires Sep 25, 2045

    granted
  9. US 12415843

    Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

    The Regents of the University of California · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  10. US 12415866

    Monoclonal antibody inhibitor of Factor XIIa

    Takeda Pharmaceutical Company Limited · Granted Sep 16, 2025 · Expires Sep 11, 2045

    granted
  11. US 12410249

    Low dose antibody-based methods for treating hematologic malignancies

    Actinium Phamaceuticals, Inc. · Granted Sep 9, 2025 · Expires Sep 4, 2045

    granted
  12. US 12384853

    Anti-HER2/PD1 bispecific antibody

    SUNSHINE GUOJIAN PHARMACEUTICAL (SHANGHAI) CO., LTD. · Granted Aug 12, 2025 · Expires Aug 7, 2045

    granted
  13. US 12371503

    Methods of treatment using a leptin receptor agonist antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  14. US 12370264

    Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject

    Dyne Therapeutics, Inc. · Granted Jul 29, 2025 · Expires Jul 24, 2045

    granted
  15. US 12357703

    Muscle-targeting complexes comprising an anti-transferin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping

    Dyne Therapeutics, Inc. · Granted Jul 15, 2025 · Expires Jul 10, 2045

    granted
  16. US 12344665

    Treatment of fibrodysplasia ossificans progressiva by administration of an anti-activin a antibody

    REGENERON PHARMACEUTICALS, INC. · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  17. US 12343394

    CD38 modulating antibody agents

    BLACK BELT THERAPEUTICS LIMITED · Granted Jul 1, 2025 · Expires Jun 26, 2045

    granted
  18. US 12337199

    Stable antibody formulation

    REGENERON PHARMACEUTICALS, INC. · Granted Jun 24, 2025 · Expires Jun 19, 2045

    granted
  19. US 12331107

    Methods of treating pneumonia or respiratory failure associated with COVID-19 by administering an anti-LIGHT antibody

    AVALO THERAPEUTICS, INC. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  20. US 12329825

    Muscle targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of use thereof to induce exon skipping of exon 44 of dystrophin in a subject

    Dyne Therapeutics, Inc. · Granted Jun 17, 2025 · Expires Jun 12, 2045

    granted
  21. TW 202523278

    Antibody drug conjugate platforms

    BEIGENE LTD [KY] · Granted Jun 16, 2025 · Expires Jun 11, 2045

    granted
  22. US 12325753

    Method of using an anti-transferrin receptor antibody to deliver an oligonucleotide to a subject having facioscapulohumeral muscular dystrophy

    Dyne Therapeutics, Inc. · Granted Jun 10, 2025 · Expires Jun 5, 2045

    granted
  23. US 12319729

    Anti-Staphylococcus aureus specific antibody and nucleic acid encoding sequence thereof, and uses of the same

    China Medical University Hospital · Granted Jun 3, 2025 · Expires May 29, 2045

    granted
  24. US 12319744

    Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein C receptor (EPCR)

    The Board of Regents of the University of Texas System · Granted Jun 3, 2025 · Expires May 29, 2045

    granted